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Introduction 
Guillain-Barre´ syndrome (GBS) is the major cause of acute neuromuscular.(Hughes 
RAC, 2007)  The term GBS includes a set of clinical syndromes with a common 
pathophysiological basis; an acute inflammatory polyneuropathy with an autoimmune etiology. 
Although usually characterized by a progressive flaccid paralysis with areflexia a wide range of 
motor, sensory and autonomic symptoms could be seen. In general, the diagnosis is based on 
clinical criteria; nevertheless, the presence of suggestive findings in the complementary test as 
demyelinating changes in the nerve conduction studies (NCS) or albuminocytological dissociation 
in the cerebrospinal fluid (CSF), help to confirm the diagnosis. (Gonzales-Suarez I, 2013) 
The worldwide incidence of GBS is reported to be 0.6-2.4 cases per 100,000 per year [8-
15]. The classic form, the acute inflammatory demyelinating polyradiculoneuropathy (AIDP), is 
the most frequent subtype in Europe, which accounts for 90% of GBS cases. Other subtypes like 
the axonal forms or the Miller-Fisher syndrome (MFS) are less common. (Gonzales-Suarez I, 
2013) 
 
 
Main Features of GBS 
The main features of GBS are rapid progressive bilateral and relative symmetrical 
weakness of the limbs with or without involvement of respiratory or cranial nerve-innervated 
muscles or sensory disturbances. Patients have decreased or absent tendon reflexes. 
Cerebrospinal fluid examination typically shows an increased protein level with a normal white 
cell count. Pain frequently occurs and may cause severe complaints. It often starts before the 
onset of weakness and therefore can lead to diagnostic difficulties. Electromyography (EMG) can 
be helpful in confirming the diagnosis in clinically difficult cases such as in patients with extreme 
pain. EMG is especially useful for subclassifying GBS into subgroups such as acute motor axonal 
neuropathy (AMAN) and acute inflammatory demyelinating polyneuropathy (AIDP). 
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Clinical Course of GBS 
Rapidly progressive weakness is the core clinical feature of GBS. By definition, maximal 
weakness is reached within 4 weeks, but most patients reach it within 2 to 3 weeks. Thereafter, 
patients enter a plateau phase that ranges from days to several weeks or months. This phase is 
followed by a usually much slower and variable recovery phase. In Europe, about one-third of 
GBS patients remain able to walk (“mild patients”); about 25% of the GBS patients who are unable 
to walk (“severe patients”) need artificial ventilation. This is predominantly due to weakness of the 
respiratory muscles. Despite standard treatment with intravenous immunoglobulin (IVIG) or 
plasma exchange (PE) treatment, about 20% of severely affected patients remain unable to walk 
after 6 months. Moreover, many patients remain otherwise disabled or severely fatigued. Even 3 
to 6 years after onset, GBS has a great impact on social life and the ability to perform activities of 
daily life. Therefore, GBS remains a severe disease for which better treatments are required. (van 
Doorn PA, Ruts L, Jacobs BC, 2008) 
 
 
 
 
Table 1. Disability Scale for GBS (Hughes RAC, 2007) 
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Immunobiology (van doorn, 2010) 
AIDP is much more common than axonal forms in the Western world. Experimental 
evidence implicates autoantibodies to gangliosides as the cause of the axonal subgroups of GBS 
and of Fisher syndrome. These autoantibodies may be generated by the immune response to an 
infective organism, such as Campylobacter jejuni, cross-reacting with epitopes on the axon. The 
resemblance of AIDP to experimental autoimmune neuritis suggests pathogenetic mechanisms 
involving T-cell induced macrophageassociated demyelination. This proposed autoimmune 
aetiology led to the introduction of immunotherapy. Before its introduction, 10% of patients died 
and 20% were left seriously disabled. Plasma exchange (PE) was introduced as a possible 
treatment in 1978 and was shown to offer significant benefit by a randomized trial published in 
1985. It became the gold standard against which other treatments were measured. (Hughes RAC, 
2007) 
There is convincing evidence that GBS at least in some patients is caused by an infection-
induced aberrant immune response that damages the peripheral nerves. Four key factors were 
identified that control this process: (van Doorn PA, Ruts L, Jacobs BC, 2008) 
 
1. Anti-ganglioside antibodies 
In up to 50% of patients, serum antibodies to various gangliosides present in human peripheral 
nerves, including GM1, GD1a, GalNAc-GD1a, and GQ1b, can be demonstrated. Other 
antibodies may bind to mixtures or complexes of different gangliosides instead of individual 
ones. Interestingly, most of these antibodies are related to defined clinical subgroups of GBS. 
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2. Molecular mimicry and cross-reactivity 
C. jejuni isolates from GBS patients express lipooligosaccharides (LOS) that mimic the 
carbohydrates of gangliosides. The type of ganglioside mimic in C. jejuni seems to determine 
the specificity of the anti-ganglioside antibodies and the associated variant of GBS. Antibodies 
in these patients usually are cross-reactive; they recognize LOS as well as gangliosides or 
ganglioside complexes. GBS after Campylobacter infection in anti-GM1/GD1a/GQ1b antibody-
related cases is considered to be true example of molecular mimicry-related disease. 
3. Complement activation 
Postmortem studies demonstrated that local complement activation occurs at the side of nerve 
damage. A mice model for GBS showed that some anti-ganglioside antibodies are toxic for 
peripheral nerves and can cause blockade of nerve transmission and paralysis of the nerve-
muscle preparation. Additionally, there is destruction of the nerve terminal and perisynaptic 
Schwann cells. Antibodies to GM1 affect the sodium channels at the nodes of Ranvier of rabbit 
peripheral nerves. All of these effects appear to be dependent on complement activation and 
formation of the membrane attack complex. The neurotoxic effects of these antibodies can be 
inhibited by IVIG and the complement inhibitor eculizumab. 
4. Host factors 
Less than 1:1,000 patients with a C. jejuni infection will develop GBS. Host factors may 
influence this susceptibility to develop GBS or the extent of nerve damage and outcome. Single 
nucleotide polymorphisms (SNPs) showed no consistent association with the susceptibility to 
develop GBS. Evidence indicates, however, that these SNPs may be important as disease-
modifying factors. An association has been demonstrated between disease severity or 
outcome and SNPs in genes encoding for mannose-binding lectin, FcγRIII, MMP9, and TNF-
α. However, confirmation in more extensive studies is required. 
 
Table 2. Spectrum of GBS subtypes and serum antiganglioside antibodies  
(van Doorn PA, Ruts L, Jacobs BC, 2008) 
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Treatment of GBS 
Treatment of GBS has two components: supportive care and specific therapy. Supportive 
care remains the cornerstone of therapy. If patients advance past the acute phase of illness, most 
will recover function. However, the neuropathy can advance so rapidly that endotracheal 
intubation and mechanical ventilation may be necessary within 24 hours of symptom onset. For 
this reason, all patients who have GBS should be admitted to a hospital for close observation for 
respiratory compromise, cranial nerve dysfunction, and autonomic instability. Autonomic nervous 
system dysfunction may manifest as fluctuations in blood pressure, cardiac dysrhythmias, 
gastrointestinal pseudo-obstruction, and urinary retention. Prophylaxis for deep venous 
thrombosis should be provided because patients frequently are immobilized for many weeks. As 
respiratory muscles weaken, elective endotracheal intubation should be considered. Progression 
to respiratory failure can be predicted using measurable respiratory parameters. Patients who are 
unable to demonstrate this minimal lung function require intubation. Frequent reassessment with 
serial lung function testing for rapid progression is critical. Additional predictors of subsequent 
mechanical ventilation include the following:  
 
1. time from GBS onset to hospital admission of less than seven days,  
2. inability to lift the elbows or head above the bed  
3. inability to stand 
4. ineffective coughing  
5. increased liver enzyme levels 
 
Predictors of mechanical ventilation in patients who had a previously determined vital 
capacity included time from GBS onset to admission of less than seven days, an inability to lift 
the head, and a vital capacity less than 60 percent predicted. One retrospective study21 
demonstrated a 40 percent decrease from predicted vital capacity, compared with a 60 percent 
decrease reported in another study. This discrepancy may be related to different study methods 
and the larger number of patients enrolled in the latter study. Pain and psychologic stress should 
be treated. Narcotics should be used with caution because risk of ileus is already increased. 
Physical therapy, including gentle massage, passive range-of-motion exercises, and frequent 
position changes may provide pain relief. Carbamazepine and gabapentin have been used as 
adjuncts in pain management in GBS. Patients who were treated with these medications required 
less narcotic analgesia with fewer narcotic side effects and minimal sedation compared with those 
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who received placebo. Patients are paralyzed by the illness, but mentally alert and fearful. 
Reassurance and discussion about the phases of illness and recovery can help reduce 
psychologic stress. 
Specific treatment should be initiated soon after diagnosis. High-dose intravenous 
immunoglobulin (IVIg; 400 mg per kg daily for five days) or plasmapheresis/plasma exchange 
(five exchanges over five to eight days) can be initiated. To determine whether IVIg was as 
effective as plasma exchange in treating patients with GBS, a large multicenter trial was designed 
to compare plasma exchange and IVIg and the combination of both treatments for GBS. The 
study followed 150 patients over four weeks. There were no statistically significant differences in 
the disability rating between the two treatment groups. IVIg and plasmapheresis were found to be 
equally effective therapies.  
 
A. Use of Plasma Exchange in GBS 
Therapeutic PE is an efficacious treatment option for patients with inflammatory 
neuropathies and is considered a first-line therapy in conditions such as AIDP. The basic 
mechanism for PE is the elimination of offending toxins or pathologic autoimmune antibodies from 
the bloodstream through extracorporeal separation from blood components. During PE, a 
patient's plasma and cells are separated through centrifugation or a filtration process. While the 
cells are reinfused into the patient, the plasma is replaced by a substitute fluid, usually albumin 
or fresh frozen plasma at a volume of 45 to 50 mL/kg. Plasma exchange requires two large bore 
access sites at alternate locations with a central line generally necessary due to the high flow 
volumes associated with treatment. Although effective, PE is invasive and can be time consuming, 
inconvenient, and overly burdensome to some. It also requires specialized personnel within an 
institutional setting who are able to run the necessary equipment. (Sederholm BH, 2010) 
In addition to vascular access or technical complications, the use of PE may be further 
thwarted by troublesome or intolerable adverse reactions. Patients undergoing PE should be 
closely monitored for hypotension, infection, bleeding complications, and hypocalcemia. Chest 
pain, tachycardia, bradycardia, fever, rash, itching, nausea, vomiting, flushing, and dizziness may 
also occur in patients undergoing PE. More severe complications, including pulmonary embolism, 
sepsis, and anaphylactic shock have also been reported.  
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B. Use of IVIG in Immune-mediated Neuropathies (benson Sedeholm, 2010, seminar in 
neurolgy) 
IVIG is a first-line agent for the treatment of many neurologic disorders including chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), 
and GBS. The mechanism of action is not fully known, but it is thought to involve modulation of 
cellular and humoral immune system processes including antibody neutralization, complement 
attenuation, and the regulation of cytokine, B cell, and T cell activity. Therapeutic IVIG product is 
derived from the isolation of immunoglobulin from multiple human donor sources. The final 
product comes from a highly involved process involving plasma fractionation, purification, 
stabilization, and virus inactivation and removal. Commercially available IVIG products vary in 
how they are formulated and manufactured. Because of this, clinical impact is not insignificant 
and product differences should be considered when evaluating the clinical efficacy and safety of 
IVIG therapy for a given patient. Components to consider include volume load, infusion rate, 
osmolality, sodium content, sugar content, pH, and IgA content. Products with a higher sugar 
component may not be suitable for patients who are elderly, have diabetes, or at risk for renal 
dysfunction. Likewise products high in salt or osmolality may be a problem in patients with cardiac 
diseases, renal dysfunction, risk for venous thromboembolism, and in elderly or pediatric 
populations. As the incidence of adverse events may be related to patient characteristics, 
individualized products and their unique components should be evaluated judiciously. (Sederholm 
BH, 2010) 
A potentially major problem with currently available IVIg preparations is the transmission 
of blood born pathogens, especially the non-A non-B (NANB) hepatitis of hepatitis C virus (HCV). 
It is difficult to estimate the risk of NANB infection following IVIg. The presence of HCV RNA 
(documented by PCR) in plasma pools prepared for anti-HCV negative units demonstrates the 
limitation of methods used to test plasma donations. In addition, the detection of HCV RNA in 
Cohn Fraction II prepared from these anti-HCV negative units and available data from patient 
treated with IVIg suggest that it is not possible to be sure that any of the products made until 
recently is completely free of NANB hepatitis. Thus, further procedures capable of maximizing the 
inactivation of NANB hepatitis are crucial for the increased safety of IVIg. One example of such 
method is the solvent detergent (S/D) treatment of plasma and its derivatives, which has been 
proven to result in HcV inactivation. Thus, an S/D virus inactivated IVIg preparation is likely to be 
HCV-free. Octagam® is an S/D virus inactivated IVIg with a physiogically distributed IgG subclass 
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and half life of 28 ± 3 days in primary hypogammaglobulinemic patients and 21 ± 3 days in Chronic 
Lymphocytic Leukemia patients. (Brenner 1996) 
 
Table 3.  Intravenous Immunoglobulin Product Comparison (Sederholm BH, 2010) 
Product 
Labeled 
Indication 
Available 
Doses 
Product 
Form 
Half-
life 
(days) 
IgG 
Content 
IgA 
Content 
Sodium 
Content 
Osmolality 
Sugar 
Content 
pH Infusion Rate Filtration 
Carimune NF 
(CSL Behring 
LLC, Kankakee, 
IL) 
PID ITP 
3, 6, 12 
gram vials 
Lyophilized 
powder 
21 ≥96% 
720 
μg/mL 
<20 mg 
per gram 
of 
protein 
192-1074 
mOsm/kg 
based upon 
diluent and 
concentration 
1.67 
grams of 
sucrose 
per gram 
of 
protein 
6.4–
6.8 
Initial: 0.5 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 3 
mg/kg/min 
Not required 
Flebogamma 5% 
DIF (Grifols 
Biologicals Inc., 
Los Angeles, CA) 
PID 
0.5, 2.5, 5, 
10, 20 
gram vials 
Liquid 30–45 ≥97% 
<50 
μg/mL 
<3.2 
mEq/L 
240–370 
mOsm/L 
5 g/100 
mL D-
sorbitol 
5.0–
6.0 
Initial: 0.5 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 5 
mg/kg/min 
Recommended 
15–20 micron 
Gammagard 
liquid 10% 
(Baxter 
Healthcare 
Corporation, 
Westlake Village, 
CA) 
PID 
1, 2.5, 5, 
10, 20 
gram vials 
Liquid 35 98% 
Average 
37 
μg/mL 
Not 
detected 
240–300 
mOsmol/kg 
None 
4.6–
5.1 
Initial: 0.8 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 8.9 
mg/kg/min 
Not required 
Gammagard S/D 
(Baxter 
Healthcare 
Corporation, 
Westlake Village, 
CA) 
PID ITP 
KS CLL 
2.5, 5, 10 
gram vials 
Lyophilized 
powder 
37.7 90% 
<1 
μg/mL 
in 5% 
solution 
8.5 
mg/mL 
636 - 1250 
mOsm/L 
based upon 
concentration 
5%: 20 
mg/mL 
glucose 
6.4–
7.2 
Initial: 0.5 
mL/kg/h 
Titrate as 
tolerated to 
maintenance 
rate of 4 
mL/kg/h (8 
mL/kg/h for 
10% solution) 
Required 15 
micron 
Gamunex 
(Talecris 
Biotherapeutics, 
Inc., Research 
Triangle Park, 
NC) 
PID ITP 
CIDP 
1, 2.5, 5, 
10, 20 
gram vials 
Liquid 35 98% 
Average 
46 
μg/mL 
Trace 
258 
mOsmol/kg 
None 
4.0–
4.5 
Initial: 1–2 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 8 
mg/kg/min 
Not required 
Octagam 5% 
(Octapharma 
USA Inc., 
Hoboken, NJ) 
PID 
1, 2.5, 5, 
10, 25 
gram vials 
Liquid 40.7 96% 
≤0.2 
mg/mL 
≤30 
mmol/L 
310–380 
mOsmol/kg 
100 
mg/mL 
maltose 
5.1–
6.0 
Initial: 0.5 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 
3.33 
mg/kg/min 
Not required 
Privigen 10% 
(CSL Behring 
LLC, Kankakee, 
IL) 
PID ITP 
5, 10, 20 
gram vials 
Liquid 36.6 98% 
≤25 
μg/mL 
Trace 
240–440 
mOsmol/kg 
None 
4.6–
5.0 
Initial: 0.5 
mg/kg/min 
Titrate as 
tolerated to 
maintenance 
infusion of 4–8 
mg/kg/min 
Not required 
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The primary component of IVIG is immunoglobulin G, which is responsible for its 
therapeutic effects. The usual effective dose of IVIG for inflammatory neuropathies is 2 g per kg 
body weight, typically divided over 2 to 5 days. The rationale for this dose was initially based upon 
earlier studies of patients with idiopathic thrombocytopenia. The optimal dose of IVIG for 
neurologic disorders is not conclusively known. Following IVIG infusion, immunoglobulin G rapidly 
distributes within the intravascular and extravascular compartments with a peak serum 
concentration typically seen within 72 hours of infusion. Although serum levels of IVIG are 
generally not measured, a recent pharmacokinetic study of IVIG in AIDP patients suggested that 
the change in serum immunoglobulin G levels may be predictive of therapeutic responses. The 
half life of IVIG is ~20 days and immunoglobulins are primarily cleared in the plasma. Dosing of 
IVIG is typically done using total body weight. For obese patients (>100 kg), many clinicians use 
an adjusted body weight based upon IVIG pharmacokinetics. 
 
 
Figure 2. Variations in course of disease in GBS. Indicated are the courses of disease in mildly and severely affected GBS 
patients. The effect of IVIG in GBS has only been investigated in randomized controlled trials in patients unable to walk unaided 
at nadir (severely affected patients) and not in mildly affected patients (able to walk unaided at nadir). Whether mildly affected 
GBS patients may also benefit from IVIG is yet unknown. GBS patients who initially improve or stabilize after IVIG and 
subsequently deteriorate again have a “treatment-related fluctuation” (GBS-TRF): a condition that usually responds to an 
additional IVIG dose. Some GBS patients have a severe course of disease and a slow recovery phase. The prognosis of GBS 
patients can be determined using the Erasmus GBS Outcome Scale. Whether a second IVIG dose is effective in patients with 
a poor prognosis is not known yet 
 
IVIG is generally well tolerated. Common adverse reactions include chills, fever, 
headache, fatigue, rigors, tremor, nausea, myalgias, malaise, and infusion-related reactions. 
More serious adverse events occur less frequently and include anaphylaxis, aseptic meningitis, 
acute renal failure, and venous thromboembolism. All patients receiving IVIG should have their 
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vital signs checked at least every 15 minutes during the first hour of infusion and periodically 
thereafter. Surveillance for tolerability and adverse events should be done judiciously with each 
infusion session. Pretreatment with acetaminophen, antihistamines, such as diphenhydramine, 
or corticosteroids may help prevent or minimize adverse events. Markers of renal function should 
be monitored before each IVIG infusion and periodically thereafter. Appropriate chemical or 
physical prophylaxis for venous thromboembolism is also warranted. Too rapid rate of infusion 
may contribute to the incidence of adverse effects. Typically, IVIG infusions are initiated at a slow 
rate and increased based upon patient tolerability. At any point during an infusion the rate can be 
decreased to improve tolerability. In general, patients with renal dysfunction should have their rate 
of infusion decreased by one half of the normal infusion rate. IVIG is expensive and its availability 
may be limited in some centers. The clinical decision to use IVIG over alternative therapies should 
be done on an individualized basis and include such factors as pregnancy, disease severity, 
patient comorbidities, and tolerability. 
Plasma Exchange vs IVIg in GBS  
IVIg was introduced for GBS in 1988. In 1992, the first randomized trial comparing IVIg 
and PE showed similar effects from each treatment. Corticosteroids were introduced for GBS in 
the early 1950s. The first randomized trial, of ACTH, published in 1976 did not show a significant 
effect but the most recent trial reported possible minor short-term benefit when high dose 
intravenous methylprednisolone was combined with IVIg. The significance of this benefit has been 
debated. (HughesRAC, 2007) 
 
 
Table 4. Common Adverse Reactions and Complications during administration of PE and IVIG 
Table 2.  Summary of Plasma Exchange and Intravenous Immunoglobulin in the Management of Guillain-Barré 
Syndrome/Acute Inflammatory Demyelinating Polyradiculoneuropathy 
Interventional Regimen Common Adverse Reactions Severe Complications 
Plasma exchange 5 
treatments over 7 to 14 days 
Hypotension, arrhythmias, infection, 
malaise, fever, flushing, dizziness, 
hypocalcemia 
Pneumothorax, hemorrhagic complications, 
sepsis, thromboembolism, anaphylaxis 
Intravenous immune 
globulin 0.4 g/kg daily for 5 
days 
Headache, myalgia, chills, fever, nausea, 
vomiting, fatigue, tremor, infusion site 
reactions 
Acute renal failure, thromboembolism, 
aseptic meningitis, myocardial infarction, 
anaphylaxis 
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Clinical trials comparing IVIG to PE indicate equal benefit between the two treatment 
options in GBS. A Cochrane systematic review of six clinical trials found no difference in the 
change of disability scores with IVIG compared with PE at 4 weeks (RR = 1.09; 95% CI: 0.94-
1.27). Other nonsignificant differences between IVIG and PE included no difference in the time 
needed to recover unassisted walking and the time until discontinuation of ventilator support in 
severe AIDP patients. This review also found that patients treated with IVIG tended to have fewer 
adverse events, fewer treatment complications, and were less likely to discontinue therapy as 
compared with PE. Complications with PE included infection, thrombosis, and hypotension. The 
largest trial in the systematic review included 383 severe AIDP patients who were randomized to 
receive IVIG 0.4 g/kg daily for 5 days, a course of five plasma exchanges administered over 8 to 
13 days, or a combination of a 5-day course of PE followed by a 5-day course of IVIG therapy. All 
patients received interventions within 14 days of symptom onset. For the primary outcome of 
mean improvement in disability score at week 4 from randomization, no difference was observed 
between treatment groups. Combination therapy was not superior to IVIG or PE alone. Study 
authors suggested that due to the convenience of IVIG administration, as compared with PE, it 
represents a more favorable treatment option in the bulk of circumstances. A Quality Standards 
Subcommittee of the American Academy of Neurology endorsed IVIG as equivalent therapy to 
PE for AIDP patients. Combination therapy with PE and IVIG was not recommended. The 
Subcommittee further recommended that IVIG be used promptly within 2 to 4 weeks of disease 
onset in severe AIDP patients unable to walk without assistance. The usual IVIG treatment 
regimen is 0.4 g/kg given daily for 5 days. For patients with inadequate response or who relapse 
following IVIG administration, a repeat course of IVIG may be beneficial. (Sederholm BH, 2010) 
 
Prognosis   
Approximately 85 percent of patients with GBS achieve a full and functional recovery 
within 6 to 12 months. Recovery is maximal by 18 months past onset. However, some patients 
have persistent minor weakness, areflexia, and paresthesia. Approximately 7 to 15 percent of 
patients have permanent neurologic sequelae including bilateral footdrop, intrinsic hand muscle 
wasting, sensory ataxia, and dysesthesia. (Newswanger DL, Warren CR, 2004) 
Death rate is described to be between 1-18%. (González-Suárez I et al, 2013)  The 
mortality rate is less than 5 percent in tertiary care centers with a team of medical professionals 
who are familiar with GBS management. Causes of death include adult respiratory distress 
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syndrome, sepsis, pulmonary emboli, and cardiac arrest. Several factors during the acute phase 
of illness predict subsequent poor recovery. These factors include age older than 60 years; 
severe, rapidly progressive disease; and low nerve conduction amplitudes on distal stimulation, 
which suggests axonal loss.  
In addition, prolonged mechanical ventilation for more than one month and preexisting 
pulmonary disease predict a poor outcome. In general, a poor long-term prognosis is directly 
related to the severity of the acute episode and delay in onset of specific treatment. Relapse 
occurs in a small percentage of patients. One multicenter trial18 of 229 patients showed a relapse 
rate of 3 to 5 percent. In that study, the relapse rate was not significantly affected by treatment 
type or any other factor tested. 
 
Conclusions 
 
In GBS patient, the administration of IVIG is thought to involve modulation of cellular and humoral 
immune system processes including antibody neutralization, complement attenuation, and the 
regulation of cytokine, B cell, and T cell activity.  
Current treatment guidelines recognize PE and IVIG as equally efficacious agents for the 
treatment of GBS/AIDP. Both agents are clinically proven to hasten the time to recovery and 
improve disability scores when administered within the early stages of disease progression. 
Patients treated with IVIG tended to have fewer adverse events, fewer treatment complications, 
and were less likely to discontinue therapy as compared with PE. Because of this, along with its 
ease of administration, IVIG is often recommended over PE therapy.  
Combination therapy was not superior to IVIG or PE alone, thus are not recommended. 
For patients with only mild forms of AIDP, few data are available to clarify the role of PE and IVIG. 
Despite effective therapies and supportive measures, residual functional deficits may persist in 
approximately one third of patients who experience AIDP.  
A Quality Standards Subcommittee of the American Academy of Neurology endorsed IVIG as 
equivalent therapy to PE for AIDP patients. The Subcommittee further recommended that IVIG 
be used promptly within 2 to 4 weeks of disease onset in severe AIDP patients unable to walk 
without assistance. 
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